Plus Therapeutics Granted Continued Nasdaq Listing with Conditions
ByAinvest
Wednesday, Aug 13, 2025 9:35 pm ET1min read
PSTV--
The company recently announced that it filed a prospectus for the sale of 33 million shares of common stock by the selling stockholder. This move is part of Plus Therapeutics' strategy to bolster its financial position and ensure compliance with Nasdaq's listing requirements [1].
Analysts have a positive outlook on Plus Therapeutics, with a majority rating the stock as a "buy" and a median 12-month price target of $8.00. However, the company faces significant financial challenges, including negative equity and ongoing losses. In its latest earnings report, Plus Therapeutics is expected to post a loss of 9 cents per share, with revenue projected to rise by 16.2% to $1.486 million for the quarter ending June 30, 2025 [2].
Despite these challenges, the company's stock has shown resilience, with analysts expecting it to rebound. Plus Therapeutics' historical earnings data indicate a mixed performance, with some quarters showing significant beats and others missing estimates [2]. The company's ability to navigate these challenges and meet the required conditions will be crucial in determining its long-term success.
References:
[1] https://seekingalpha.com/news/4484250-plus-therapeutics-files-to-sell-33m-shares-of-common-stock-for-holders
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U01X6:0-plus-therapeutics-inc-expected-to-post-a-loss-of-9-cents-a-share-earnings-preview/
Plus Therapeutics (PSTV) has been granted continued Nasdaq listing after failing to meet the minimum stockholders' equity requirement of $2.5 million. The company must meet specific conditions by August 14 and September 8, 2025, to maintain its listing. Analysts rate PSTV a buy with a $8.00 price target, but the stock faces significant financial challenges with negative equity and ongoing losses.
Plus Therapeutics Inc. (NASDAQ: PSTV), a biotechnology company focused on developing innovative therapeutic solutions, has been granted a continued listing on the Nasdaq Stock Market after failing to meet the minimum stockholders' equity requirement of $2.5 million. The company must adhere to specific conditions set by the Nasdaq Stock Market to maintain its listing, including meeting certain financial thresholds by August 14 and September 8, 2025 [1].The company recently announced that it filed a prospectus for the sale of 33 million shares of common stock by the selling stockholder. This move is part of Plus Therapeutics' strategy to bolster its financial position and ensure compliance with Nasdaq's listing requirements [1].
Analysts have a positive outlook on Plus Therapeutics, with a majority rating the stock as a "buy" and a median 12-month price target of $8.00. However, the company faces significant financial challenges, including negative equity and ongoing losses. In its latest earnings report, Plus Therapeutics is expected to post a loss of 9 cents per share, with revenue projected to rise by 16.2% to $1.486 million for the quarter ending June 30, 2025 [2].
Despite these challenges, the company's stock has shown resilience, with analysts expecting it to rebound. Plus Therapeutics' historical earnings data indicate a mixed performance, with some quarters showing significant beats and others missing estimates [2]. The company's ability to navigate these challenges and meet the required conditions will be crucial in determining its long-term success.
References:
[1] https://seekingalpha.com/news/4484250-plus-therapeutics-files-to-sell-33m-shares-of-common-stock-for-holders
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U01X6:0-plus-therapeutics-inc-expected-to-post-a-loss-of-9-cents-a-share-earnings-preview/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet